RecruitingPhase 4NCT03844360

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Sponsor

Wei Zhao

Enrollment

1,500 participants

Start Date

Jan 31, 2016

Study Type

INTERVENTIONAL

Conditions

Hematological Neoplasms

Summary

The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.

Eligibility

Min Age: 1 DayMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Anti-Infective Drugs, a drug called Bortezomib, and others for people with hematological neoplasms. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 1 Day to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBortezomib

bortezomib was administered follow the doctor's advice.

DRUGEltrombopag

eltrombopag was administered follow the doctor's advice.

DRUGImatinib

imatinib was administered follow the doctor's advice.

DRUGdasatinib

dasatinib was administered follow the doctor's advice.

DRUGPegaspargase

pegaspargase was administered follow the doctor's advice.

DRUGAnti-Infective Drugs

anti-infective drugs was administered follow the doctor's advice.

DRUGPEGylated Recombinant Human Granulocyte Colony-Stimulating Factor

pegaspargase was administered follow the doctor's advice.

Locations(2)

Department of Pediatrics, the Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China

State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Tanjin, Tianjin Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03844360

Related Trials

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

NCT069040661 location

Distraction With Virtual Reality From Pain and Anxiety for Patients With Hematological Malignancies

NCT070850651 location